Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05184569 · ClinicalTrials.gov registry record · Phase 1
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
A Phase 1 study of Semantic Dementia, sponsored by Peter Ljubenkov, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 5
- Study locations
NCT05184569 is a Phase 1 study of Semantic Dementia that is actively recruiting participants, run by Peter Ljubenkov, MD. The registered enrollment target is 64 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT05184569, a Phase 1 study of Semantic Dementia, is actively recruiting participants, sponsored by Peter Ljubenkov, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and one-fourth will receive Placebo during the 24-week treatment duration.
Conditions Studied
Interventions
- DRUG Verdiperstat
Study Locations (5)
California
- UCSF Memory and Aging Center - San Francisco
Illinois
- Northwestern University - Chicago
Minnesota
- Mayo Clinic - Rochester
Pennsylvania
- University of Pennsylvania - Philadelphia
Texas
- Houston Methodist Hospital - Nantz National Alzheimer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2022-04-14 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05184569
The ClinicalTrials.gov registry entry for NCT05184569 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peter Ljubenkov, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Semantic Dementia appearing as the primary indexed condition, and to 1 intervention - of which Verdiperstat is the first listed.
NCT05184569 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Illinois, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05184569 about?
NCT05184569 is a clinical study titled "Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology". The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and...
What is the current status of trial NCT05184569?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2022-04-14. Estimated completion is 2026-09-30.
What conditions does trial NCT05184569 study?
This clinical trial studies the following conditions: Semantic Dementia.
What interventions are being tested in trial NCT05184569?
The interventions under investigation include: Verdiperstat (DRUG).
Who is sponsoring clinical trial NCT05184569?
This trial is sponsored by Peter Ljubenkov, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05184569 being conducted?
This trial has 5 study locations across California, Illinois, Minnesota, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Semantic Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.